Results

Total Results: 406 records

Showing results for "company".

181. Comparative Effectiveness Review Disposition of Comments Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bundled-payments-quality-effects_disposition-comments.pdf
     August 24, 2012 - Comparative Effectiveness Review Disposition of Comments Report Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and- reports/?pageaction=displayproduct&productID=1235 Published Online: August 24, 2012 Comparative Effectiveness Research Review Disposition of Comments Report Research …

182. Future Research Needs for Diagnosis of Obstructive Sleep Apnea (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/sleep-apnea-diagnosis-future_research.pdf
     February 01, 2012 - Future Research Needs for Diagnosis of Obstructive Sleep Apnea Future Research Needs Paper Number 11 Future Research Needs for Diagnosis of Obstructive Sleep Apnea Future Research Needs Paper Number 11 Future Research Needs for Diagnosis of Obstructive Sleep Apnea Identification of Future Research …

183. Tonsillectomy Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/tonsillectomy_research-protocol.pdf
     February 10, 2016 - FDA  510Ka  approvals   Product   Company   Decision  Date   510(K)   Number   Peak  PlasmaBlade  TNA

184. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1312.pdf
     October 01, 2014 - the phase III BROADEN (Brodmann Area 25 Deep Brain Neurostimulation).41 According to a July 2011 company … pathway for this indication and its availability for off-label use.68,93 Several institutions and one company

185. Disposition of Comments Report for Enzyme-Replacement Therapies for Lysosomal Storage Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/lysosomal-storage-diseases-therapies_disposition-comments.pdf
     January 01, 2014 - Now that there is more than one company involved, there is no one complete patient data base. … For diseases with more than one company involved, there is more than one registry (i.e.

186. Disposition of Comments for Technical Brief 22 Environmental Cleaning for the Prevention of Healthcare-Associated Infections (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/healthcare-infections_disposition-comments.pdf
     August 10, 2015 - We have removed company names to be fair to all environmental services contractors.

187. Disposition of Comments for Comparative Effectiveness Review No. 240: Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-revised-comments.pdf
     December 29, 2020 - Disposition of Comments for Comparative Effectiveness Review No. 240: Treatments for Acute Pain: A Systematic Review Comparative Effectiveness Review Disposition of Comments Report Research Review Title: Treatments for Acute Pain: A Systematic Review Draft report available for public comment from August 31, 2020,…

188. S44 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s44.pdf
     October 01, 2007 - The rheumatologists and the pharmaceutical company representatives concluded that withholding funding

189. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_disposition-comments.pdf
     September 01, 2011 - Peer Reviewer 3 Discussion/ Conclusion The contribution of data from a company with a profit-motive

190. Methods Guide for Medical Test Reviews Chapter 6 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-applicability_methods.pdf
     July 01, 2012 - on a version that provides dichotomous, qualitative results (present versus absent), and that the company

191. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers L…

192. Smoking-Pregnancy-Infants Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/smoking-pregnancy-infants_research-protocol.pdf
     March 11, 2013 - Nicotine replacement therapy products Product Company Administration Prescription NRT products Nicotrol … Non-nicotine replacement therapy drugs Drug Trade Name Company Administration FDA Pregnancy Category

193. 15 Crosscutting Potential High Impact 2012-12-11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/15_crosscutting_potential_high_impact_2012-12-11.pdf
     January 01, 2012 - The company received marketing clearance from the U.S. … July 2012, FDA cleared the ingestible sensor technology for marketing in the United States. 17 The company

194. Disposition of Comments for Technical Brief 36: Strategies for Patient, Family, and Caregiver Engagement (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/technical-brief-36-patient-engagement-comments.pdf
     August 26, 2020 - based on out of primary care, and maybe that same message is not well received from their insurance company … I would expect that within any company/industry, employee satisfaction strongly influences and impacts

195. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ischemic-stroke-treatment_research-protocol.pdf
     February 19, 2010 - Evidence-based Practice Center Systematic Review Protocol Source: www.effectivehealthcare.ahrq.gov Published Online: February 19, 2010 1 Evidence-based Practice Center Systematic Review Protocol Project Title: Technical Brief: Neurothrombectomy Devices for Treatment of Acu…

196. Disposition of Comments for Use of Natriuretic Peptide Measurement in the Management of Heart Failure (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_disposition-comments.pdf
     November 20, 2013 - Disposition of Comments for Use of Natriuretic Peptide Measurement in the Management of Heart Failure Comparative Effectiveness Review Disposition of Comments Report Research Review Title: Use of Natriuretic Peptide Measurement in the Management of Heart Failure Draft review available for public comme…

197. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
     April 01, 2013 - About half the studies were either sponsored by one company or the investigators stated they had a conflict … I wonder if the company is aware of other studies that were not published because of negative findings

198. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/gestational-diabetes-screening-diagnosis_research-protocol.pdf
     December 16, 2011 - Pharmaceutical company funding and its consequences: a qualitative systematic review.

199. The Evidence-Based Care Challenge: A Case Study (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ebc-challenge-case-130621.pdf
     June 01, 2013 - For example, Netflix, a company that provides on-demand media streaming and mail-order DVD rental, launched

200. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - larger, higher-quality studies have almost all been conducted with new drugs with pharmaceutical company